Internal Medicine, Hematology & Oncology · Prescott, AZ
NPI
1902853294
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
5430 Landmark Ln
Prescott, AZ, 86301
Phone (928) 775-9430
Groups this clinician bills Medicare through
Medicare paid, 2024
$5.0M
243,168 services
Medicare patients, 2024
1,180
Average age 76
Drug cost, 2024
$7.9M
2,768 prescriptions
Company payments, 2025
$2,732
From 37 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Alan D Langerak was code J9271 (injection, pembrolizumab, 1 mg), 26,800 times for 35 patients. In total Alan D Langerak billed 243,168 services in 148 codes, and Medicare paid $5.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-10-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 26,800 | 35 | $44.68 | $1.2M |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 14,700 | 14 | $2.32 | $34K |
| J0897 Injection, denosumab, 1 mg | Office | 12,540 | 67 | $20.64 | $259K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 11,400 | 18 | $0.11 | $1,272 |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 11,057 | 94 | $0.10 | $1,138 |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 10,620 | 15 | $39.31 | $417K |
| J0185 Injection, aprepitant, 1 mg | Office | 9,750 | 30 | $1.35 | $13K |
| J9267 Injection, paclitaxel, 1 mg | Office | 6,978 | 15 | $0.08 | $549 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 3,800 | 31 | $15.88 | $60K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 3,460 | 96 | $0.09 | $306 |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 1,840 | 59 | $0.25 | $459 |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 1,812 | 11 | $36.60 | $66K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,780 | 55 | $0.66 | $1,175 |
| 99214 Office E&M - Established | Office | 1,516 | 771 | $91.76 | $139K |
| 96375 Injection Administration | Office | 900 | 116 | $11.56 | $10K |
By year: 2022 $5.6M for 319,785 services; 2023 $5.1M for 268,181 services; 2024 $5.0M for 243,168 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 12 | 11 | $8.65 | $104 |
Medicare prescription drug claims, 2024
In 2024, the drug Alan D Langerak prescribed most often to Medicare patients was Anastrozole, with 474 prescriptions and refills. In total Alan D Langerak wrote 2,768 Medicare prescriptions that cost $7.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 474 | 1,205 | 142 | $8,628 |
| Ondansetron Hcl Generic | 153 | 154 | 100 | $1,420 |
| Acyclovir Generic | 143 | 198 | 34 | $1,653 |
| Hydroxyurea Generic | 128 | 293 | 34 | $2,098 |
| Calquence Acalabrutinib Maleate | 111 | 111 | 11 | $1.6M |
| Dexamethasone Generic | 109 | 113 | 37 | $2,076 |
| Eliquis Apixaban | 108 | 154 | 23 | $85K |
| Letrozole Generic | 99 | 243 | 27 | $2,379 |
| Prednisone Generic | 81 | 99 | 31 | $585 |
| Exemestane Generic | 74 | 182 | 27 | $11K |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 66 | 73 | 37 | $752 |
| Prochlorperazine Maleate Generic | 55 | 55 | 35 | $456 |
| Lenalidomide Generic | 55 | 55 | Under 11 | $720K |
| Levothyroxine Sodium Generic | 53 | 100 | 17 | $500 |
| Olanzapine Generic | 47 | 47 | 32 | $334 |
Brand drugs: 628 claims; generic drugs: 2,140 claims; opioid claims: 65.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Alan D Langerak $2,732 ($2,732 in general payments such as food, travel and fees) from 37 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $278.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 9 | $278 |
| Janssen Biotech, Inc. JNJ | 11 | $258 |
| E.R. Squibb & Sons, L.L.C. BMY | 11 | $161 |
| Daiichi Sankyo Inc. 4568.T | 5 | $141 |
| Pfizer Inc. PFE | 8 | $139 |
| Abbvie Inc. ABBV | 4 | $121 |
| Genmab U.S., Inc. GMAB | 5 | $121 |
| Eisai Inc. 4523.T | 5 | $108 |
| Geron Corporation GERN | 3 | $94.99 |
| Merck Sharp & Dohme LLC MRK | 3 | $87.1 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.